嗜乳酸杆菌联合兰索拉唑阿莫西林克拉霉素治疗顽固性幽门螺杆菌感染的临床研究

Clinical Study of Supplementation Lactobacillus Acidophilus on Lansoprazole Amoxycillin and Clarithromycin Triple Therapy Regimens for Persistent Helicobacter Pylori Infection

目的探讨嗜乳酸杆菌制剂(乐托尔)联合兰索拉唑阿莫西林克拉霉素三联疗法对幽门螺杆菌(Helicobacter pylori,Hp)顽固性感染的治疗效果。方法将80例Hp顽固性感染患者分为两组,分别采用兰索拉唑三联疗法、乐托尔联合兰索拉唑三联疗法治疗10天。结果两组患者治疗10天后,兰索拉唑三联组和乐托尔联合兰索拉唑三联组Hp清除率分别为94.8%和97.56%,两组间无明显统计学差异;然而,兰索拉唑三联治疗组中,13例患者出现不同程度的不良反应,明显高于乐托尔联合兰索拉唑三联组(4例)(P<0.05)。结论乐托尔联合兰索拉唑三联治疗方案治疗不仅具有良好的Hp清除效果,而且不良反应少,因此,为顽固性Hp感染患者的治疗提供了新的思路。

Objective To evaluate the method for treatment of persistent Helicobacter pylori （Hp） infection. Methods 80 patients with persistent Hp infection were divided into two groups, and treated by LAC triple therapy regimens （Lansoprazole, Amoxycillin and Clarithromycin） and L＋LAC therapy regimens （Lactobacillus acidophilus, Lansoprazole, Amoxycillin and Clarithromycin）, respectively. Resuits Hp eradication rates were 94.8% and 97.56% in LAC group and L＋LAC group, respectively （P 〉 0.05）. However, the patients had side-effects in LAC group was much more than that in L＋ LAC group （13 patients to 4 patients） （P 〈 0. 05）. Conclusions Lactobacillus acidophilus, Lansoprazole, Amoxycillin and Clarithromycin therapy regimens is a better ways for the treatment of persistent Hp infection because of its better acceptance of patients.